Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: Radium-223 Dichloride vs ARPI in mCRPC
NCT04597125Phase 4Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2020
- Primary completion
- Nov 2025
- Modality
- Radiopharmaceutical
- Countries
- 19
01
Overview
Phase 4, randomised, open-label trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Bayer. Started Nov 2020; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04597125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04597125.